SOP on Process Validation update (068)
SOP on Process Validation update (068)
Dhaka, Bangladesh
1 PURPOSE
To describe the procedure for carrying out process validation activities of the product.
2 SCOPE
This procedure is applicable for all products manufactured at The ACME Laboratories Ltd.
Dhaka, Bangladesh.
3 RESPONSIBILITIES
3.1 Executive, R&D (FRD) is Responsible to –
3.1.1 Submit the Master Formula (MF) to QA (Where applicable).
3.1.2 Prepare process validation protocol and report of new product and existing product.
3.1.3 Execute PV batches as per protocol.
3.1.4 Prepare process verification protocol and report.
3.1.5 Join as a team member of continued/ongoing process verification.
3.2 Manager, R&D (FRD)/Nominee is Responsible to –
3.2.1 Check process validation/verification protocol and report.
3.2.2 Ensure proper execution of PV batches.
3.2.3 Review continued/ongoing process verification calendar.
3.2.4 Check thecontinued/ongoing process verification protocol and report.
3.3 Executive, Production is Responsible to–
3.3.1 Prepare the Batch Manufacturing Record (BMR) and Batch Packaging Record (BPR) based
on corresponding master formula.
3.3.2 Execute PV batches as per protocol.
3.3.3 Provide all supports for execution of PV batches.
3.4 Head of Production/Nominee is Responsible to –
3.4.1 Check process validation/verification protocol and report.
3.4.2 Review the continued/ongoing process verification calendar.
3.4.3 Check the continued/ongoing process verification protocol & report.
3.5 Executive, Validation is Responsible to –
3.5.1 Prepare continued/ongoing process verification calendar.
5 ASSOCIATED DOCUMENTS
Preparation, Review and Approval of Process Validation : SOP/ACME-VAL/067
Protocoland Report
Procedure for New Product Development : SOP/ACME-R&D/002
Preparation, Review, & Distribution of Master Formulation (MF),
: SOP/ACME-R&D/012
Batch Manufacturing Record& Batch Packaging Record (BPR)
7 PRECAUTION
7.1 Only the trained personnel on respective SOPs are eligible to be involved in the process
validation activities.
7.2 Raw and packaging materials availability must be ensured by user department before
execution of PV batches.
8 PROCEDURE
8.1 Process Validation activities will be performed in three stages:
8.1.1 Stage-1: Process Design
8.1.1.1 Raise a change control for introduction of new product based on product development study.
8.1.1.2 Define CQA, CPP&CMA through risk assessment, during product development.
8.1.1.3 Run scale up/ process optimization batches (as per requirement) following SOP for Carry out
Process Optimization Batch in GMP Facility (SOP/ACME-R&D/006).
8.1.1.4 After successful completion of Scale up/ Process optimization batch proceed for Stage-2:
Process Qualification/ Process Validation.
8.1.2 Stage-2: Process Qualification/ Process Validation
8.1.2.1 Prepare the PV BMR, BPR and Protocolbased on corresponding master formula and scale
up/ process optimization report if PO is done.
8.1.2.2 Preparethe check list for process validation activities (Appendix-A) in case of new product,
transfer product & full validation/ re-validation.
8.1.2.3 Take decision to proceed as per Appendix-A.
8.1.2.4 Provide training on the approved protocol as per Appendix-A of PV Protocol before
execution of PV batches.
8.1.2.5 Issue the approved BMR & BPR according to SOP: SOP/ACME-QA/021.
8.1.2.6 Issue the approved protocol and relevant appendices to production by stamping the QA
issued seal on the top of the first page of protocol. Stamp the batch number on first page of
8.1.4.9 Consider the area in case of change of equipment, process & specification as mentioned in
the below table (but not limited to)-
Compression Machine/
Encapsulation Machine/ Core & Coating
Encapsulation stage
Bottle or Sachet Filling stage Filling Stage
Machine
Equipment
Granulation,
Granulation Blending, Core & N/A N/A
Coating stage
Blending,
Blending, Core & Blending &
Blending Filling &
Coating Stage Encapsulation Stage
Sealing
9 REFERENCES
9.1 Rules and Guidance of Pharmaceutical Manufacturers and Distributors; Annex 15:
Qualification and Validation.
9.2 WHO Technical Report Series No. 1019, WHO Expert Committee on Specifications for
Pharmaceutical Preparations Fifty-Third Report.
9.3 ICH Guideline [ICH Q8].
9.4 FDA: Guidance for Industry (Process Validation: General Principles and Practices).
10 APPENDICES
A. CHECK LIST FOR PROCESS VALIDATION ACTIVITIES (FORMAT).
B. CHECK LIST FOR PROCESS VALIDATION FILE (FORMAT).
C. CONTINUED/ONGOING PROCESS VERIFICATION CALENDAR (FORMAT).
D. PROCESS VALIDATION FLOW CHART.
2. Precaution 7.3 has been excluded and a new precaution has been
added in 7.5.
3. Responsibility 3.5 & 3.8 have been modified.
4. The procedures have been modified and updated [8.9, (8.11-
procedure 8.11 split into three points 8.11.1, 8.11.2 & 8.11.3),
8.14.2, 8.15.2 serial no. 4].
5. Procedures 8.15.4 & 8.15.5 have been newly added.
6. Reference 9.3 has been newly added.
7. In Appendix –A, option for specification & analytical report sheet
for intermediate, bulk & finished product has been added (Serial
No. 8).
8. In Appendix-B, option for ‘statically evaluation report of process
data’ has been included & option for ‘calibration status’ has been
excluded.
9. Change control reference no. CCR/SDU/19/655.